# Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

> **NCT04210115** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 703 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)
- Gastroesophageal Junction Carcinoma (GEJC)
- Esophageal Adenocarcinoma (EAC)

## Interventions

- **BIOLOGICAL:** pembrolizumab
- **DRUG:** placebo
- **DRUG:** cisplatin
- **DRUG:** 5-FU
- **RADIATION:** radiotherapy
- **DRUG:** leucovorin
- **DRUG:** levoleucovorin
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT04210115
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-28
- **Primary completion:** 2026-01-21
- **Final completion:** 2026-06-26
- **Target enrollment:** 703 (ACTUAL)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04210115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04210115, "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT04210115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*